- Home
- ARGX vs CTVA Comparison
ARGX vs CTVA Comparison
Compare ARGX & CTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- CTVA
- Stock Information
- Founded
- ARGX 2008
- CTVA 2018
- Country
- ARGX Netherlands
- CTVA United States
- Employees
- ARGX N/A
- CTVA 22000
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- CTVA Farming/Seeds/Milling
- Sector
- ARGX Health Care
- CTVA Consumer Staples
- Exchange
- ARGX Nasdaq
- CTVA Nasdaq
- Market Cap
- ARGX 51.1B
- CTVA 44.6B
- IPO Year
- ARGX 2017
- CTVA N/A
- Fundamental
- Price
- ARGX $917.87
- CTVA $66.91
- Analyst Decision
- ARGX Strong Buy
- CTVA Strong Buy
- Analyst Count
- ARGX 17
- CTVA 17
- Target Price
- ARGX $910.63
- CTVA $77.63
- AVG Volume (30 Days)
- ARGX 367.0K
- CTVA 4.1M
- Earning Date
- ARGX 10-30-2025
- CTVA 11-04-2025
- Dividend Yield
- ARGX N/A
- CTVA 1.08%
- EPS Growth
- ARGX N/A
- CTVA 139.00
- EPS
- ARGX 23.27
- CTVA 2.35
- Revenue
- ARGX $3,683,281,000.00
- CTVA $17,469,000,000.00
- Revenue This Year
- ARGX $85.93
- CTVA $6.19
- Revenue Next Year
- ARGX $35.17
- CTVA $3.44
- P/E Ratio
- ARGX $36.91
- CTVA $28.39
- Revenue Growth
- ARGX 92.98
- CTVA 5.00
- 52 Week Low
- ARGX $510.06
- CTVA $53.40
- 52 Week High
- ARGX $934.13
- CTVA $77.41
- Technical
- Relative Strength Index (RSI)
- ARGX 70.28
- CTVA 61.53
- Support Level
- ARGX $897.50
- CTVA $63.56
- Resistance Level
- ARGX $932.29
- CTVA $66.59
- Average True Range (ATR)
- ARGX 19.86
- CTVA 1.42
- MACD
- ARGX -0.28
- CTVA 0.28
- Stochastic Oscillator
- ARGX 82.07
- CTVA 97.94
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
About CTVA Corteva Inc.
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva plans to spin off its seeds business in 2026 and will become a pure-play crop protection company following the divestiture. Corteva operates globally, but around half of revenue comes from North America.